In Vitro Comparison of Terbinafine and Itraconazole against Penicillium marneffei

ABSTRACT We evaluated terbinafine and itraconazole against 30 isolates ofPenicillium marneffei using a modification of the National Committee for Clinical Laboratory Standards broth macrodilution MIC testing protocol for yeasts. The minimal fungicidal concentration (MFC) was determined by plating 100 μl from each MIC drug dilution having no growth onto Sabouraud glucose agar incubated at 30°C. The MFC was the dilution at which growth was absent at 72 h of incubation. The MICs, in micrograms per milliliter, were as follows: terbinafine, 0.03 to 1.0 (geometric mean titer, 0.09); itraconazole, 0.03 to 0.5 (geometric mean titer, 0.04). The MFCs, in micrograms per milliliter, were as follows: terbinafine, 0.03 to 8 (geometric mean titer, 2.60); itraconazole, 0.03 to 8 (geometric mean titer, 2.45). Primary fungicidal activity (MFC within 2 dilutions of MIC) was observed with terbinafine in eight isolates and with itraconazole in four isolates. The data indicate that terbinafine is active against P. marneffei in vitro and may have a previously unrealized role in the management of infections caused by this fungus.

[1]  M. Mcginnis,et al.  In vitro evaluation of terbinafine and itraconazole against dematiaceous fungi. , 1998, Medical mycology.

[2]  M. Mcginnis,et al.  In Vitro Testing of Susceptibilities of Filamentous Ascomycetes to Voriconazole, Itraconazole, and Amphotericin B, with Consideration of Phylogenetic Implications , 1998, Journal of Clinical Microbiology.

[3]  M. Rinaldi,et al.  In vitro evaluation of voriconazole against some clinically important fungi , 1997, Antimicrobial agents and chemotherapy.

[4]  K. Nishimura,et al.  Random amplified polymorphic DNA (RAPD) analysis ofPenicillium marneffei strains isolated from AIDS patients in Thailand , 1997 .

[5]  K. Yazawa,et al.  In vitro antifungal activity of the new triazole D0 870 against Penicillium marneffei compared with that of amphotericin B, fluconazole, itraconazole, miconazole and flucytosine , 1996, Mycoses.

[6]  J. W. Taylor,et al.  Phylogeny and PCR identification of the human pathogenic fungus Penicillium marneffei , 1995, Journal of clinical microbiology.

[7]  K. Nelson,et al.  Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens , 1993, Antimicrobial Agents and Chemotherapy.

[8]  M. Mcginnis,et al.  Pathology of Penicillium marneffei. An emerging acquired immunodeficiency syndrome-related pathogen. , 1997, Archives of pathology & laboratory medicine.

[9]  B. Dupont,et al.  Infection à Penicillium marneffei: mycose systémique à manifestations cutanées associée au SIDA , 1995 .